Single Domain Antibody (SdAb) based Antibody-Drug Conjugate (ADC) Development Solution

SdAb-based ADC Development Workflow Features Case Study

Creative Biolabs is dedicated to discovering unique single domain antibodies for our clientele all over the world. We are now offering sdAb-based antibody-drug conjugate (ADC) development service and our scientists have built up end-to-end solutions to generate high-quality sdAb-based ADC with complete technical support.

Antibody-drug conjugates (ADCs) have pioneered a novel domain in targeted therapeutics by integrating the precise targeting capabilities of biologics with the potent cytotoxic effects of small molecule drugs. To date, several ADCs that rely on full-sized antibodies have been FDA approved and with a large pipeline in clinical trials. However, the complex structure of full-sized antibodies makes it hard to penetrate deeply into tumor tissues, limiting the therapeutic effect of ADCs.

Developing High-Quality SdAb-based ADC at Creative Biolabs

At present, Creative Biolabs provides a new solution to this challenge by utilizing single domain antibodies (sdAbs) instead of full-length IgG or other antibody fragments for the development of novel antibody-drug conjugates (ADCs). sdAb has the smallest size (15 kDa) among all types of antibody analogs while containing the full antigen-binding domains. The small size endows sdAbs with the capability of epitope recognition when target antigens are densely packed and cryptic. Moreover, sdAbs have remarkable tissue penetration due to their relatively small molecular size and compact spatial structure. Moreover, their single-domain structure facilitates efficient phagemid-based screening and offers extensive opportunities for site-specific modifications without affecting the binding properties of the modified sdAbs.

Collectively, sdAb-based ADC is a desirable strategy for developing the next generation of ADCs for research, diagnostic, and therapeutic purposes. Our comprehensive solution offers an optimal and highly effective approach to achieving your objectives with a significant success rate. With the help of highly experienced staff, Creative Biolabs offers different sdAb-based conjugates based on radioactive tracers, nanomaterials, gene products, immunomodulatory, cytotoxic reagents, or a combination. The new generation of sdAb-based ADCs showed remarkable targetability, higher antitumor efficacy, and low systemic side effects in therapeutic and diagnostic applications, especially for improving targeted delivery. In summary, we will offer a promising platform to generate sdAb-based ADCs, which will show remarkable targetability, higher antitumor efficacy, and low systemic side effects in both therapeutic and diagnostic applications, especially for improving targeted delivery.

Typical Pathway for SdAb-based ADC Development

Phase I Discovery

arow
arow

Phase II Characterization

arow

Phase III Development

VHH -Drug Conjugate Development
VHH-Drug Conjugate Development
VHH Half-life Extension
VHHalf-life Extension
arow

Phase IV Manufacture

Typical Features of One-Stop for SdAb-based ADC Development

Creative Biolabs is committed to supporting sdAb-based ADC development projects with exceptional quality and efficiency. Leveraging our robust platform and experienced scientists, we are confident in providing tailored, comprehensive solutions to meet your specific needs. For further information, please do not hesitate to contact us.

We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.

Online Inquiry
Interested in our expertise?

Contact us for more information

Get free consultations
USA
  • Tel:
  • Fax:
  • Email:
UK
  • Tel:
  • Email:
Germany
  • Tel:
  • Email:

Enter your email here to subscribe.

Submit

Follow us on

ISO 9001 Certified - Creative Biolabs Quality Management System.
Copyright © 2025 Creative Biolabs. All Rights Reserved.